Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials.
Lamotrigine monotherapy did not demonstrate efficacy in the acute treatment of bipolar depression in four out of five placebo-controlled clinical studies, but was well tolerated inThe results of five randomized, double-blind, placebo- controlled trials of lamotrigin monotherapy were reported. Expand
Factors That Affect Adherence to Bipolar Disorder Treatments: A Stated-Preference Approach
- F. Johnson, Semra Özdemir, R. Manjunath, A. Hauber, S. Burch, Thomas R. Thompson
- Medical care
- 1 June 2007
Patients with bipolar disorder are suggested to be more adherent to medications that reduce the severity of depressive episodes and do not cause weight gain or cognitive side effects by understanding the factors that improve adherence. Expand
Predictors of bipolar disorder risk among patients currently treated for major depression.
- J. Calabrese, D. Muzina, +6 authors R. Hirschfeld
- MedGenMed : Medscape general medicine
- 15 August 2006
Comorbid anxiety, feelings of people being unfriendly, recent depression diagnosis, BPD family history, and legal problems may prove useful indicators of BPD risk among patients who have failed at least 1 antidepressant. Expand
Maintenance treatment outcomes in older patients with bipolar I disorder.
- M. Sajatovic, L. Gyulai, +4 authors G. Evoniuk
- Psychology, Medicine
- The American journal of geriatric psychiatry…
- 1 April 2005
Lamotrigine and lithium may be effective and well-tolerated maintenance therapies for older adults with Bipolar I depression. Expand
The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder.
- N. Calvert, S. Burch, A. Fu, P. Reeves, Thomas R. Thompson
- Journal of managed care pharmacy : JMCP
- 1 May 2006
The pharmacoeconomic model indicated that prevention of mood episodes with lithium and lamotrigine is cost effective in patients with a recent manic, mixed, or hypomanic episode and cost-effectiveness of maintenance treatments for patients with BD-I are likely to improve in models with a broader costing perspective and that take a longer time frame. Expand
Lamotrigine as Add-On Therapy in Schizophrenia: Results of 2 Placebo-Controlled Trials
- D. Goff, R. Keefe, +6 authors E. Webster
- Psychology, Medicine
- Journal of clinical psychopharmacology
- 1 December 2007
Results from these 2 studies do not support the use of lamotrigine as an adjunct to atypical antipsychotics in patients with refractory psychosis, and the positive effect of lamo on cognition in one trial, while of uncertain significance, may merit further study. Expand
Apomorphine: Clinical studies on erectile impotence and yawning
- S. Lal, Y. Tesfaye, +5 authors B. Dubrovsky
- Medicine, Psychology
- Progress in Neuro-Psychopharmacology and…
- 31 December 1989
Spontaneous and Apo-induced yawning were significantly decreased in the elderly which suggests that D2 receptor function declines with normal aging, and is compatible with the view that Apo HC1 in doses of 3.5-5.0 ug/kg stimulates presynaptic DA receptors whereas 7.0Ug/ kg stimulates postsynapticDA receptors. Expand
Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder.
Lamotrigine was associated with stable body weight during 1 year of treatment and was comparable to placebo in mean weight change, incidence of clinically significant weightchange, and incidence of weight changes reported as adverse events in patients with bipolar I disorder. Expand
Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder.
- C. Bowden, J. Calabrese, T. Ketter, G. Sachs, Robin L White, Thomas R. Thompson
- The American journal of psychiatry
- 1 July 2006
Obese patients with bipolar I disorder lost weight while taking lamotrigine and gained weight whileTaking lithium while taking lithium. Expand
A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
- J. Barbee, Thomas R. Thompson, +5 authors R. Shelton
- Psychology, Medicine
- The Journal of clinical psychiatry
- 22 February 2011
Results of the primary efficacy analysis of the randomized patients using the MADRS, HDRS-17, CGI-S, and CGI-I did not demonstrate a statistically significant difference between lamotrigine and placebo groups, although some secondary analyses were suggestive of efficacy. Expand